India

COVID-19 Coronavirus Pandemic – Latest Media Coverage

"Dr Reddy"

Latest news and video coverage curated from trusted media outlets


0 shares	Share Tweet Save Post Send



Equity indices trade higher, pharma stocks rally Equity benchmark indices traded higher during early hours on Friday amid mixed cues from their Asian peers. At 10:15 am, the BSE S-P Sensex was up by 136 points or 0.35 per cent at 39,115 while the.. Credit: ANI Duration: 01:24Published 2 weeks ago

Equity indices nudge lower on weak global cues, banking stocks dip Equity benchmark indices traded lower during early hours on Thursday on the back of weak global cues after the US Federal Reserve indicated the interest rate could stay close to zero for years. At.. Credit: ANI Duration: 01:09Published 2 weeks ago

Closing bell: Equity indices in positive terrain, Dr Reddy's top gainer Equity benchmark indices traded higher in the afternoon session on September 16 while Asian stocks were flat ahead of the US Federal Reserve's view on the economy. The BSE S-P Sensex closed 259 points.. Credit: ANI Duration: 01:21Published 2 weeks ago

Russian Direct investment fund partners with Dr. Reddy's for Sputnik V trials in India\|Oneindia News Dr Reddy's and the Russian Direct Investment Fund (RDIF) have agreed to conduct clinical trials and distribute 100 million doses of Russia's Sputnik V Covid-19 vaccine in India. The RDIF is Russia's.. Credit: Oneindia Duration: 01:03Published 2 weeks ago

Equity indices spurt with rally in banking scrips, IndusInd up 12 pc Equity benchmark indices traded higher on the first day of September futures and options series with banking and financials contributing significantly to the gains. The BSE S and P Sensex closed 354.. Credit: ANI Duration: 01:13Published on August 28, 2020

Equity indices dip on weak global cues, pharma stocks hit Equity benchmark indices drifted lower during early hours on Wednesday amid weak global cues with pharma stocks losing the most. At 10:15 am, the BSE SandP Sensex was down by 181 points or 0.47 per.. Credit: ANI Duration: 01:11Published on August 12, 2020

Equity indices close in the green, Cipla gains 9.5 pc Equity benchmark indices shaved off early gains but ended in the positive terrain on Monday with pharma stocks leading the rally. At the closing bell, the BSE SandP Sensex was up by 142 points or 0.37.. Credit: ANI Duration: 01:17Published on August 10, 2020

Equity indices gain 1% on global cues, metal stocks shine Equity benchmark indices were on upswing during early hours on August 05 amid positive global cues with metal and banking stocks leading the rally. At 10:15 am, the BSE SandP Sensex was up by 408.. Credit: ANI Duration: 01:04Published on August 5, 2020

You Might Like

DRL launches generic of Precedex Dr. Reddy’s has unveiled Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Hospira’s Preced Hindu - Published 4 days ago
Mitesh Thakkar: BUY TCS, Dr Reddy’s; SELL Axis Bank and BPCL TopNews - Published 6 days ago
India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks Indian trials of the Sputnik-V vaccine candidate, being developed by Russia`s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals.. DNA - Published 1 week agoAlso reported by •IndiaTimes

The Hindu Explains \| What do we know about Russia’s COVID-19 vaccine candidate Sputnik V? How will the tie-up with Dr. Reddy’s Laboratories help India? Hindu - Published 1 week ago
Equity indices close lower on profit booking, Dr Reddy's up 10 pc newKerala.com - Published 1 week ago
Dr Reddy’s shares extend rally; zoom over 10% On the NSE, it zoomed 9.92% to close at ₹ 5,306. Hindu - Published 2 weeks ago

DRL, Celgene settle Revlimid patent suit Pharma major Dr. Reddy’s Laboratories and Celgene, a wholly owned subsidiary of Bristol Myers Squibb, have settled their litigation relating to patent Hindu - Published 2 weeks ago
COVID-19 vaccine to be available in India by early 2021: Union Health Minister Harsh Vardhan Meanwhile, Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of the world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds.. DNA - Published 2 weeks ago
COVID-19 vaccination to be available by 'start of next year': Harsh Vardhan Union Health Minister Harsh Vardhan on Thursday said that the coronavirus vaccine will be made available in the country by the start of next year. The remarks come at a time when India is recording.. Mid-Day - Published 2 weeks ago
Russia, Dr Reddy’s tie up for Sputnik V trial Russia’s sovereign wealth fund – Russian Direct Investment Fund (RDIF) — has partnered Hyderabad-based drug maker Dr Reddy’s Laboratories to cooperate on clinical trials and distribution of.. IndiaTimes - Published 2 weeks ago

Dr Reddy’s inks deal to distribute 100 mn doses of Sputnik V Indian Express - Published 2 weeks ago
Russia inks pact to test, supply Sputnik V vaccine to India Agreement with Dr. Reddy’s Laboratories doesn’t include its manufacture. Hindu - Published 2 weeks ago
Russia confirms deal with Dr. Reddy's for COVID-19 vaccine 'Sputnik V' trials in India, to supply 100 million doses Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds up plans to.. DNA - Published 2 weeks ago	Russia to sell 100 million doses of Covid-19 vaccine to India Russia's sovereign wealth fund said on Wednesday it will supply India's Dr Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against Covid-19 once it receives regulatory approval... IndiaTimes - Published 2 weeks agoAlso reported by •newKerala.com •Mid-Day
Equity indices in positive terrain, Dr Reddy's top gainer newKerala.com - Published 2 weeks ago	DRL prices Remdesivir at ₹5,400 a vial Dr. Reddy’s Laboratories has unveiled Gilead Sciences’ Remdesivir, an investigational drug used in COVID-19 treatment, under the Redyx brand in India Hindu - Published 3 weeks ago
Dr Reddy's launches Remdesivir in India Pharma major Dr Reddy’s Laboratories Ltd on Wednesday announced the rollout of potential Covid-19 treatment generic drug Remdesivir, under the Redyx brand name in India. Dr Reddy’s has announced.. IndiaTimes - Published 3 weeks agoAlso reported by •Hindu